Beyond Conditional Average Effects: Quantifying Positive and Negative Causal Contributions
summary
The gist
There has been considerable interest in estimating heterogeneous causal effects across individuals or subpopulations Researchers often assess causal effect heterogeneity based on the subjects’…
In short
The research introduces P-CACE and N-CACE to decompose causal effect heterogeneity into positive and negative components for binary treatment/continuous outcome settings. New measures, P-CPICE and N-CPICE, are also developed for continuous treatments using stochastic interventions. These measures allow researchers to quantify how the average causal effect varies across different subpopulations defined by positive or negative treatment effects.
Key concepts
- P-CACE and N-CACE
- These are novel measures designed to break down the overall Conditional Average Causal Effect (CACE) into two distinct parts. P-CACE captures the causal effect experienced by subjects who are positively affected by the treatment, while N-CACE captures the effect on negatively affected subjects.
- P-CPICE and N-CPICE
- These measures extend the concept to continuous treatments and outcomes. They quantify how much of a continuous causal effect is attributable to subpopulations characterized by positive or negative treatment effects, using stochastic interventions for analysis.
- Decomposition of Causal Effect Heterogeneity
- The paper proves that the total CACE can be naturally split into P-CACE minus N-CACE. This decomposition allows researchers to understand the overall effect by separately analyzing the positive and negative causal contributions within the population.
Terminology used across episodes
This episode discusses
- Beyond Conditional Average Effects: Quantifying Positive and Negative Causal Contributions · Paper Radio
- CATE Lasso: Conditional Average Treatment Effect Estimation with High-Dimensional Linear Regression
- Quantifying Individual Risk for Binary Outcomes
The paper
Beyond Conditional Average Effects: Quantifying Positive and Negative Causal Contributions · Read on arXiv
Mohamed bin Zayed University of Artificial Intelligence
Understanding causal effect heterogeneity is important for evaluating interventions and informing individual decisions. The conditional average causal effect (CACE) summarizes how average effects vary across covariate-defined subpopulations, but it can obscure positive and negative individual effects within these subpopulations. Existing work on effect heterogeneity beyond CACE has primarily focused on binary treatments and outcomes. In this paper, we introduce two heterogeneity measures for binary treatments and continuous outcomes: P-CACE and N-CACE, that quantify the positive and absolute negative contributions of individual causal effects to CACE, respectively. Their difference equals CACE, revealing contributions that may otherwise be obscured by averaging. We further introduce their counterparts for continuous treatments and outcomes, P-CPICE and N-CPICE. They leverage stochastic interventions to broaden the range of causal questions that researchers can investigate. We establish identification and bounding theorems for these measures. An application to a medical dataset illustrates how these measures provide information about individual causal effects beyond conditional averages.
Transcript
Introduction to the show: ident: Statistics. The day in statistics: methods, theory and the inference under them.
Tom: We're looking at the paper: "Beyond Conditional Average Effects".
Title and authors: Tom: So, we’re diving into this paper called "Beyond Conditional Average Effects: Quantifying Positive and Negative Causal Contributions". It's looking at how the average causal effect across everyone—what they call the conditional average causal effect or CACE—doesn't capture all the story, especially when you look at different groups of people.
Jane: Right, so what’s this about? Basically, researchers use CACE based on some person's characteristics to estimate the effect of a treatment. But this paper suggests there’s still stuff hidden there that we aren't seeing just by looking at those known characteristics or covariates.
Tom: Exactly. They introduce two new measures called P-CACE and N-CACE, which they use when you have a binary treatment and a continuous outcome to specifically look at the CACE over the groups who actually benefit or the groups who actually get hurt by the treatment.
Lu: And what’s interesting about that is that they show you can naturally break down that overall CACE into these two parts, P-CACE and N-CACE, so you get one measure for the positive effects and another measure for the negative effects across positively and negatively affected subjects > Page two <ref:2602.08647#pg1,P-CACE and N-CACE>.
Jane: That decomposition sounds really useful because it lets us separate the good outcomes from the bad ones when we're trying to understand why some people respond well to a treatment while others don't.
Tom: And they also extend this idea into continuous treatments and continuous outcomes using something called stochastic interventions, which lets them look at more flexible scenarios for those situations > Page three <ref:2602.08647#pg3>.
Meng: From an engineering standpoint, I always wonder how these measures scale when you start dealing with high-dimensional data or really complex treatment settings; are these calculations feasible for production deployment?
Lalam: Based on the literature, this approach is trying to address a gap where existing methods focus only on binary outcomes and struggle with the continuous outcome scenarios > Page two <ref:2602.08647#pg1>.
Jane: So, Tom, can you tell us more about how they handle those continuous treatment and continuous outcome settings with these new measures? What’s the trick there?
Title and authors: Tom: Well, they use stochastic interventions to allow them to investigate more flexible scenarios for when both the treatment and the outcome are continuous things > Page three <ref:2602.08647#pg3>. They introduce P-CPICE and N-CPICE for those situations > Page three <ref:2602.08647#pg3>.
Lu: The identification theorems they establish for P-CPICE and N-CPICE rely on specific assumptions, which is important because it tells us exactly what conditions need to be met for these measures to actually work reliably > Page three <ref:2602.08647#pg3>.
Jane: That sounds like a lot of technical stuff. For someone listening who isn't reading the math, what does it mean that they established identification theorems? What’s the payoff for us?
Tom: It means they proved that if you meet those specific assumptions—like assumption one, two, three, and four—then these new measures are actually computable and give you a true estimate of the effect > Page three <ref:2602.08647#pg3>.
Meng: Computable is fine on paper, but what about running this at scale? Does the computation for these P-CPICE and N-CPICE estimates become prohibitively expensive when we have millions of data points?
Lalam: The method they used for estimating these measures involves the local linear estimator for conditional cumulative distribution functions, which is how they handled it in their experiments > Page three <ref:2602.08647#pg3>.
Jane: Okay, so the paper also shows how this works on real-world data from medicine. What did they find when they applied this to that actual dataset? Did it actually confirm what they thought?
Tom: They used the local linear estimator for conditional CDFs on a real medical dataset to estimate P-CACE, N-CACE, P-CPICE, and N-CPICE from finite samples > Page three <ref:2602.08647#pg3>.
Lu: The numerical experiments showed that even when the overall CACE or CPICE was positive, having high values for N-CACE or N-CPICE can cause decision makers to hesitate to implement the intervention > Page two <ref:2602.08647#pg1>.
Jane: That’s a really strong point because it suggests that just knowing the average effect isn't enough; you need to look at where things are going wrong for specific subgroups, which is what P-CACE and N-CACE help reveal.
Tom: And they also provided bounding results for these measures under assumptions one and three > Page three <ref:2602.08647#pg3>. Bounding results give us a range of possible values, which helps with uncertainty quantification.
Title and authors: Meng: Bounding results are helpful, but I want to know about the limitations here; what’s the catch? What assumptions is this paper making that might not hold in a real-world scenario?
Lu: One limitation they flag is that they need specific assumptions about the data and the treatment structure to establish identification for these measures > Page three <ref:2602.08647#pg3>.
Jane: So, to wrap up on these new tools, what’s the big picture implication for people who make decisions based on causal effects? What does this paper change for how we think about treatment efficacy?
Tom: It changes things by giving decision-makers a way to see if the benefit they see is coming from everyone or just a few very specific groups > Page two <ref:2602.08647#pg1>.
Jane: It suggests that focusing only on the average effect can be misleading, and these measures help pinpoint whether we’re looking at positive contributions or negative contributions within those different subgroups > Page three <ref:2602.08647#pg3>.
Lalam: The paper "Beyond Conditional Average Effects: Quantifying Positive and Negative Causal Contributions" provides novel ways to decompose causal effect heterogeneity using P-CACE, N-CACE, P-CPICE, and N-CPICE > Page one <ref:2602.08647#pg1,P-CPICE, and N-CPICE>.
Tom: It’s a significant step because it moves beyond just measuring the overall effect and starts quantifying *why* the effect is what it is by separating positive from negative contributions > Page two <ref:2602.08647#pg1>.
Jane: It opens up new avenues for understanding personalized medicine or targeted interventions, where we can see exactly who benefits and who might be harmed > Page three <ref:2602.08647#pg3>.
Lu: For future work, they are clearly pointing toward extending this analysis to even more complex treatment designs using different stochastic intervention methods > Page three <ref:2602.08647#pg3>.
Meng: I’m still thinking about the computational cost at scale, but if we can get the bounding results to hold up under more general assumptions, that would make it much more viable for production systems > Page three <ref:2602.08647#pg3>.
Lalam: This paper is providing a solid foundation for moving from simple average effects to a richer understanding of heterogeneous causal contributions across both binary and continuous settings > Page one <ref:2602.08647#pg1>.
The paper's summary: Tom: So, we’re talking about this paper "Beyond Conditional Average Effects: Quantifying Positive and Negative Causal Contributions" which is all about fixing how we look at average treatment effects by splitting them up into positive and negative parts.
Jane: Right, so before this, researchers used something called the conditional average causal effect or CACE, which is like a single number for an intervention across a whole group of people based on their known characteristics.
Tom: Exactly. But this new work introduces P-CACE and N-CACE to show that the overall CACE is actually composed of two separate things: one part that’s positive and one part that’s negative, across the subjects who are positively or negatively affected by the treatment.
Lu: The core idea here is decomposition; they prove you can take that one CACE number and break it down into P-CACE minus N-CACE, which captures those two distinct causal contributions.
Jane: That’s pretty powerful because it means when we look at a medical outcome or any intervention, we aren't just seeing the average; we are seeing exactly which parts of the population are getting better and which parts are getting worse.
Tom: It moves us from a single summary statistic to understanding the distribution of effects across subgroups, whether those treatments have binary outcomes or continuous ones.
Meng: I’m thinking about deployment here—if we’re shipping a model, how much extra computation is this decomposition adding? Are we just running two separate calculations instead of one?
Lalam: The team used methods like the local linear estimator for conditional cumulative distribution functions to estimate these measures from real-world medical data, and they found that even if the total effect was positive, high negative components could still make a decision-maker hesitate to implement something.
Jane: That’s a great point—it shows that just having a positive average isn't enough; we need to know if the negative side is overwhelming the positive side for certain patients.
Tom: And they also extended this idea to continuous treatments and outcomes using stochastic interventions, which lets them investigate those more flexible scenarios where both the treatment and what happens afterwards are continuous variables.
Lu: They established identification theorems for these continuous measures, P-CPICE and N-CPICE, under specific conditions involving stochastic interventions like do(Xpi0) and do(Xpi1). That means we have mathematical proof that these new measures can actually be calculated reliably if those assumptions hold true.
Jane: So, the implication for us is that we can get a much richer picture of treatment efficacy by separating the good effects from the bad ones across different types of data and treatment designs.
Tom: It’s about giving decision-makers a tool to see exactly where the benefit is coming from versus where it’s being lost, which is a big step beyond just looking at one overall number.
Lu: They also provided bounding results for these measures under specific assumptions, which gives us some kind of range or uncertainty quantification around those estimates.
Jane: So what this paper really changes for the world is that we can stop treating causal effects as a single fixed value and start treating them as complex distributions split into positive and negative components.
Tom: And that opens up new ways to understand personalized medicine, where we can target interventions specifically to those groups who benefit most or avoid those who might get hurt.
Lu: Next time, we’ll look at how the team tackled the identification theorems for these continuous settings and what assumptions they needed to make.
The paper's improvements: Tom: So, we’re talking about the improvements they suggest for these new measures, P-CACE and N-CACE, moving from just having a decomposition to actually being able to use them in a more robust way.
Jane: Right, so what are the authors proposing now? They’re trying to make sure these estimates don't break down when things get messy in the real world.
Tom: They’re focusing on making the identification theorems stronger, especially under those continuous treatment and continuous outcome scenarios we talked about earlier, P-CPICE and N-CPICE.
Lu: The authors are using stochastic interventions again—like do(Xpi0) and do(Xpi1)—to set up these identification conditions for the continuous case, which is how they get mathematical proof that the measures work.
Meng: Proof is great on paper, but what about running this at scale? If we have millions of data points in a continuous setting, does this approach stay manageable computationally?
Lalam: The methodology involves the local linear estimator for conditional cumulative distribution functions to handle those continuous settings, and they show that these measures are computable under assumptions one through four.
Jane: That sounds like a big step because it’s moving from theoretical possibility to actual mathematical certainty for those more complex continuous situations.
Tom: And they also provided bounding results for P-CPICE and N-CPICE under assumptions one and four, which gives us some kind of uncertainty quantification around those estimates.
Lu: Those bounding results are important because they give us a range of possible values, even when the underlying assumptions aren't perfectly met in practice.
Jane: So what this changes for someone listening who isn't reading the math is that we get more confidence in these complex measures, even if the perfect conditions aren't always met.
Tom: It’s about making sure we have a reliable range of answers instead of just one point estimate that might be shaky.
Meng: I still worry about deployment cost; if this requires running a lot of simulation steps to get those bounds, it might not be practical for real-time decisions at scale.
Lalam: The work suggests that these improvements build a solid foundation for using these measures in more complex treatment designs, pushing the analysis toward those more flexible scenarios.
Jane: And they’re clearly pointing toward extending this analysis to even more complicated treatment designs using different stochastic intervention methods down the road.
Conclusion: Tom: So we’re wrapping up this look at "Beyond Conditional Average Effects: Quantifying Positive and Negative Causal Contributions" by Tom and Jane, which is about splitting causal effects into positive and negative parts across different data types.
Jane: Basically, they showed us how to go beyond just one average number for an effect and start seeing which groups are actually getting the good stuff versus the bad stuff.
Tom: They established P-CACE and N-CACE for binary and continuous outcomes, and P-CPICE and N-CPICE for the continuous cases using those stochastic interventions we talked about.
Lu: The main point is that this decomposition gives us a much richer understanding of why some people respond differently to an intervention than others.
Meng: From a production standpoint, it means we can get more granular insights into where our models are failing or succeeding across different patient profiles, which helps with targeted fixes.
Lalam: I’m confident in my assessment; the paper provides a solid framework for moving from simple averages to this deeper understanding of causal contributions.
Jane: It opens up avenues for really personalized medicine because we can see exactly who benefits and who might be harmed by a treatment.
Tom: Exactly, it’s not just about knowing the overall result anymore; it’s about knowing the distribution of results across subgroups.
Lu: The future work is clearly pointing toward extending this analysis to even more complicated treatment designs using different stochastic intervention methods.
Meng: I still have my eye on the computational cost; if we can get those bounding results to hold up under more general assumptions, that would make it much more viable for production systems.
Lalam: This paper is providing a solid foundation for moving from simple average effects to a richer understanding of heterogeneous causal contributions across both binary and continuous settings.
Tom: So, that’s our take on this paper on "Beyond Conditional Average Effects: Quantifying Positive and Negative Causal Contributions."
Jane: It’s about getting rid of the single number trap and seeing the positive and negative drivers behind every treatment effect.
Lu: We'll be looking at how they handled those identification theorems for continuous settings in our next session.
More episodes
- Daily Summary for 2026-11-19
- 2310.07973-Statistical Performance Guarantee for Subgroup Identification with Generic Machine Learning
- 2408.09155-Learning Robust Treatment Rules for Censored Data
- Daily Summary for 2026-11-19
- 2603.23397-Kinetic Langevin Splitting Schemes for Constrained Sampling
- 2606.09906-An information-geometric framework for mapping maximum potential biodiversity
- 2603.27718-Induced replication and the assessment of models
- 1307.0898-Entropy of a Zipfian Distributed Lexicon
- 2406.19974-Generalizing self-normalized importance sampling with couplings
- 2412.10213-Collaborative Optimal Design of Controlled Experiments with Subject Covariates